Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Reuters NewMedia - September 30, 2008
The $30 million facility is a joint venture by the nonprofit Scripps Research Institute in La Jolla and the International AIDS Vaccine Initiative.
"The world needs an AIDS vaccine to turn the tide on this devastating pandemic," Dr. Richard Lerner, president of the Scripps Research Institute, said in a statement.
"We are confident that this center will facilitate more productive exchanges among researchers and stimulate new ideas that will help to accelerate AIDS vaccine science."
The center at Scripps will be dedicated to one important aspect of making a vaccine -- stimulating the production of immune system compounds called neutralizing antibodies.
The AIDS virus infects an estimated 33 million people globally, according to the United Nations, and has killed 25 million since it was identified in the 1980s.
It affects the immune system, killing cells called T-cells that usually attack invaders. Patients die of infections such as tuberculosis, or of cancer.
Cocktails of drugs can control the virus but there is no cure. And efforts to make a vaccine have failed, in part because it attacks some of the cells usually activated by immunization, and in part because no vaccine can stimulate antibodies to help kill the virus.
"Finding a way to elicit neutralizing antibodies against HIV is the biggest challenge facing AIDS vaccine researchers today," said Dr. Seth Berkley, president and chief executive officer of IAVI.
The institute will recruit biologists, virologists, chemists and immunologists to work together in the lab and run tests in human volunteers.
"This reinvigorated approach will also make it easier for us to recruit and mentor the young scientists who represent the future of HIV/AIDS vaccine research," said Dennis Burton, who works at Scripps and IAVI.
The center is not yet built and no date has been announced for its opening.
(Reporting by Maggie Fox, editing by Will Dunham and Xavier Briand)
080930
RE080932
Copyright © 2008 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .